Tatsuya Kawa

ORCID: 0009-0008-0400-7089
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Lung Cancer Research Studies
  • CAR-T cell therapy research
  • Cancer therapeutics and mechanisms
  • Immunotherapy and Immune Responses
  • Nanoplatforms for cancer theranostics
  • Monoclonal and Polyclonal Antibodies Research

Abstract Small-cell lung cancer (SCLC) is an aggressive for which immune checkpoint inhibitors (ICI) have had only limited success. Bispecific T-cell engagers are promising therapeutic alternatives ICI-resistant tumors, but not all patients with SCLC responsive. Herein, to integrate CD137 costimulatory function into a engager format and thereby augment efficacy, we generated CD3/CD137 dual-specific Fab engineered DLL3-targeted trispecific antibody (DLL3 trispecific). The was competitively...

10.1158/2326-6066.cir-23-0638 article EN Cancer Immunology Research 2024-04-01

Abstract Background: Despite the approval of immune checkpoint inhibitors (ICIs), prognosis small cell lung cancer (SCLC) remains poor. DLL3 is upregulated in SCLC whereas expression normal tissues minimal, representing favorable profile as a therapeutic target. T engager (TCE) potent immunotherapy that redirects cells to tumors expressing specific antigen. Unlike ICIs, TCEs do not require recognition tumor antigens by and thus could be an alternative approach target where benefit ICIs...

10.1158/1538-7445.am2023-1872 article EN Cancer Research 2023-04-04

<div>Abstract<p>Small-cell lung cancer (SCLC) is an aggressive for which immune checkpoint inhibitors (ICI) have had only limited success. Bispecific T-cell engagers are promising therapeutic alternatives ICI-resistant tumors, but not all patients with SCLC responsive. Herein, to integrate CD137 costimulatory function into a engager format and thereby augment efficacy, we generated CD3/CD137 dual-specific Fab engineered DLL3-targeted trispecific antibody (DLL3 trispecific). The...

10.1158/2326-6066.c.7267968 preprint EN 2024-06-04

<div>Abstract<p>Small-cell lung cancer (SCLC) is an aggressive for which immune checkpoint inhibitors (ICI) have had only limited success. Bispecific T-cell engagers are promising therapeutic alternatives ICI-resistant tumors, but not all patients with SCLC responsive. Herein, to integrate CD137 costimulatory function into a engager format and thereby augment efficacy, we generated CD3/CD137 dual-specific Fab engineered DLL3-targeted trispecific antibody (DLL3 trispecific). The...

10.1158/2326-6066.c.7267968.v1 preprint EN 2024-06-04
Coming Soon ...